Intraperitoneal chemotherapy for women with ovarian cancer: Nursing care and considerations

Clinical Journal of Oncology Nursing

Volumn 12, Issue 2, 2008, Pages 265-271

  Potter, Kamala L ^a   Held Warmkessel, Jeanne ^b  

^a LEHIGH VALLEY HOSPITAL   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; CASE REPORT; DRUG CONTRAINDICATION; FEMALE; HUMAN; INFUSION; METHODOLOGY; MIDDLE AGED; MORTALITY; NURSING; NURSING ASSESSMENT; ONCOLOGY NURSING; OVARIECTOMY; OVARY TUMOR; PATIENT EDUCATION; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MIDDLE AGED; NURSING ASSESSMENT; ONCOLOGIC NURSING; OVARIAN NEOPLASMS; OVARIECTOMY; PATIENT EDUCATION AS TOPIC; PATIENT SELECTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 45549098925     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/08.CJON.265-271     Document Type: Article

References (50)

1. Alberts, D.S., Liu, P.Y., Hannigan, E.V., O'Toole, R., Williams, S.D., Young, J.A., et al. (1996). Intraperitoneal cisplatin plus intra-venous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New England Journal of Medicine, 335(26), 1950-1955.
2. Alberts, D.S., Markman, M., Muggia, F., Ozols, R.F., Eldermire, E., Bookman, M.A., et al. (2006). Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer. Gynecologic Oncology, 103(3), 783-792.
3. Alhayki, M., Hopkins, L., & Le, T. (2006). Intraperitoneal chemotherapy for epithelial ovarian cancer. Obstetrical and Gynecological Survey, 61(8), 529-534.
4. Almadrones, L. (2007). Evidence-based research for intraperitoneal chemotherapy in epithelial ovarian cancer. Clinical Journal of Oncology Nursing, 11(2), 211-216.
5. American Cancer Society. (2008). Cancer facts and fgures 2008. Retrieved March 8, 2008, from http://www.cancer.org/down loads/STT/2008CAFFfnalsecured.pd
6. Armstrong, D.K., Bundy, B.N., Wenzel, L., Huang, H.Q., Baergen, R., Lele, S., et al. (2006). Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine, 354(1), 34-43.
7. Bristow, R.E., Tomacruz, R.S., Armstrong, D.K., Trimble, E.L., & Montz, F.J. (2002). Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. Journal of Clinical Oncology, 20(5), 1248-1259.
8. Cannistra, S. (2006). Intraperitoneal chemotherapy comes of age. New England Journal of Medicine, 354(1), 77-79.
9. Casper, E.S., Kelsen, D.P., Alcock, N.W., & Lewis, J.L., Jr. (1983). IP cisplatin in patients with malignant ascites: Pharmacokinetic evaluation and comparison with the IV route. Cancer Treatment Reports, 67(3), 235-238.
10. Claus, E.B., Schildkrauten, J.M., Thompson, W.D., & Risch, N.J. (1996). The genetic attributable risk of breast and ovarian cancer. Cancer, 77(11), 2318-2324.
11. Dedrick, R.L., Myers, C.E., Bungay, P.M., & DeVita, V.T., Jr. (1978). Phar-macokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treatment Reports, 62(1), 1-11.
12. DeGregorio, M.W., Lum, B.L., Holleran, W.M., Wilbur, B.J., & Sikic, B.I. (1986). Preliminary observations of intraperitoneal carbo-platin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemotherapy and Pharmacology, 18(3), 235-238.
13. Ferrell, B., Cullinane, C., Ervin, K., Melancon, C., Ulman, G., & Jurez, G. (2005). Perspectives on the impact of ovarian cancer: Women's views of quality of life. Oncology Nursing Forum, 32(6), 1143 -1149.
14. Flessner, M.F. (2005). The transport barrier in intraperitoneal therapy. American Journal of Physiology, Renal Physiology, 288(3), F433-F442.
15. Francis, P., Rowinsky, E., Schneider, J., Hakes, T., Hoskins, W., & Markman, M. (1995). Phase I feasibility and pharmacologic study of weekly interperitoneal paclitaxel: A Gynecologic Oncology Group pilot study. Journal of Clinical Oncology, 13(12), 2961-2967.
16. Fujiwara, K., Ar mstrong, D., Morgan, M., & Markman, M. (2007). Principles and practice of intraperitoneal chemotherapy for ovarian cancer. International Journal of Gynecological Cancer, 17(1), 1-20.
17. Gilda's Club. (2007). FAQs. Retrieved March 12, 2008, from http:// www.gildasclub.org/faqs.asp
18. Howell, S., Pfeife, C., Wung, W., Olshen, R.A., Lucas, W.E., Yon, J.L., et al. (1982). Intraperitoneal cisplatin with systemic thiosulfate protection. Annals of Internal Medicine, 97(6), 845-851.
19. Hydzik, C. (2007). Implementation of intraperitoneal chemotherapy for the treatment of ovarian cancer. Clinical Journal of Oncology Nursing, 11(2), 221-225.
20. Jaaback, K., & Johnson, N. (2006). Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Co-chrane Database of Systematic Reviews, 2006(1), CD005340.
21. Jones, R.B., Myers, C.E., Guarino, A.M., Dedrick, R.L., Hubbard, S.M., & DeVita, V.L. (1978). High volume intraperitoneal chemotherapy ("belly bath") for ovarian cancer. Pharmacologic basis and early results. Cancer Chemotherapy and Pharmacology, 1(3), 161-166.
22. King, M.C., Marks, J.H., & Handell, J.B. (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 302(5645), 643-646.
23. Kirmani, S., Braly, P.S., McClay, E.F., Saltzstein, S.L., Plaxe, S.C., Kim, S., et al. (1994). A comparison of intravenous versus intraperito-neal chemotherapy for the initial treatment of ovarian cancer. Gynecologic Oncology, 54(3), 338-344.
24. Krasner, C.N., Roche, M., Horowitz, N.S., Supko, J.G., Lee, S.I., & Oliva, E. (2006). Case records of the Massachusetts General Hospital. Case 11-2006: A 54-year-old woman with a mass in the pelvis. New England Journal of Medicine, 354(15), 1615-1625.
25. Lockwood-Rayermann, S. (2006). Survivorship issues in ovarian cancer: A review. Oncology Nursing Forum, 33(3), 553-562.
26. Los, G., Mutsaers, P.H., Lenglet, W.J., Baldew, G.S., & McVie, J.G. (1990). Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemotherapy and Pharmacology, 25(6), 389-394.
27. Mak hija, S., Leitao, M., Sabbatini, P., Bellin, N., Almadrones, L., Leon, L., et al. (2001). Complications associated with intraperitoneal chemotherapy catheters. Gynecologic Oncology, 81(1), 77-81.
28. Makhija, S., Sabbatini, P., & Barakat, R. (1999). Intraperitoneal chemotherapy strategies in the treatment of epithelial ovarian carcinoma. Current Opinion in Obstetrics and Gynecology, 11(1), 23-27.
29. Marin, K., Oleszewski, K., & Mueh lbauer, P. (2007). Intraperitoneal chemotherapy: Implications beyond ovarian cancer. Clinical Journal of Oncology Nursing, 11(6), 881-889.
30. Markman, M. (1996). Intraperitoneal therapy of ovarian cancer. Oncologist, 1(1-2), 18-21.
31. Markman, M., Bundy, B.N., Alberts, D.S., Fowler, J.M., Clark-Pearson, D.L., Carson, L.F., et al. (2001). Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperito-neal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 19(4), 1001-1007.
32. Markman, M., Rowinsky, E., Hakes, T., Reichman, B., Jones, B., Lewis, J.L., Jr., et al. (1992). Phase I trial of intraperitoneal taxol: A Gynecologic Oncology Group study. Journal of Clinical Oncology, 10(9), 1485 -1491.
33. Markman, M., & Walker, J.M. (2006). Intraperitoneal chemotherapy of ovarian cancer: A review, with focus on practical aspects of treatment. Journal of Clinical Oncology, 24(6), 988-994.
34. Martin, V. (2007). Ovarian cancer: An overview of treatment options. Clinical Journal of Oncology Nursing, 11(3), 201-207.
35. McGuire, W.P., Hoskins, W.J., Brady, M.F., Kucera, P.R., Partridge, E.E., Look, K.Y., et al. (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine, 334(1), 1-6.
36. Meyers, M.A., Oliphant, M., Berne, A.S., & Feldberg, M.A. (1987). The peritoneal ligaments and mesenteries: Pathways of intraab-dominal spread of disease. Radiology, 163(3), 593-604.
37. National Cancer Institute. (2004). Surveillance Epidemiology and End Results: Cancer stat fact sheets. Retrieved March 8, 2008, from http://seer.cancer.gov/statfacts/html/ovary.html?statfacts_page=ovary.html&x=8&y=17
38. National Cancer Institute. (2006). NCI issues clinical announcement for preferred methods of treatment for advanced ovarian cancer. Retrieved June 18, 2006, from http://www.nih.gov/news/pr/jan2006/nci-04.htm
39. National Comprehensive Cancer Network. (2005). NCCN clinical practice guidelines in oncology. Genetic/familial high risk assessment: Breast and ovarian. v.1.2007. Retrieved June 18, 2006, from http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf
40. O'Rourke, J., & Mahon, S.M. (2003). A comprehensive look at the early detection of ovarian cancer. Clinical Journal of Oncology Nursing, 7(1), 41-47.
41. Ozols, R.F., Bundy, B.N., Greer, B.E., Fowler, J.M., Clarke-Pearson, D., Burger, R.A., et al. (2003). Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. Journal of Clinical Oncology, 21(17), 3194 -3200.
42. Ozols, R.F., Locker, G.Y., Doroshow, J.H., Grotzinger, K.R., Myers, C.E., & Young, R.C. (1979). Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Research, 39(8), 3209-3214.
43. Raptopoulos, V., & Gourtsoyiannis, N. (2001). Peritoneal carcino-matosis. European Radiology, 11(11), 2195-2206.
44. Rothenberg, M.L., Liu, P.Y., Braly, P.S., Wilczynski, S.P., Hannigan, E.V., Wadler, S., et al. (2003). Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: Results from an intergroup phase II trial. Journal of Clinical Oncology, 21(7), 1313-1319.
45. Runyon, B.A., & Such, J. (2002). Surgical peritonitis and other diseases of the peritoneum, mesentery, omentum, and diaphragm. In M. Feldman, L.S. Friedman, & M.H. Sleisenger (Eds.), Sleisen-ger and Fordtran's gastrointestinal and liver disease (pp. 2357-2358). Philadelphia: Saunders.
46. Schneider, J.G. (1994). Intraperitoneal chemotherapy. Obstetrics and Gynecology Clinics of North America, 21(1), 195-212.
47. Sugarbaker, P. (2005). A curative approach to peritoneal carcino-matosis from colorectal cancer. Seminars in Oncology, 32(6, Suppl. 9), S68-S73.
48. Swenson, K.K., & Erikson, J.H. (1986). Nursing management of in-traperitoneal therapy. Oncology Nursing Forum, 13(5), 33-39.
49. Walker, J.L., Armstrong, D.K., Huang, H.Q., Fowler, J., Webster, K., Burger R.A., et al. (2006). Intraperitoneal catheter outcomes in a phase III trial of i ntravenous versus i ntraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology, 100 (1), 27-32.
50. Weisberger, A.S., Levine, B., & Storaasli, J.P. (1955). Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA, 159(18), 1704-1707.